Product Description: CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis[1][2].
Applications: COVID-19-immunoregulation
Formula: C16H27N5O2
References: [1]Bennett B, et, al. CC-90001, a Second Generation Jun N-Terminal Kinase (JNK) Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 2017; 195:A5409./[2]Kolb M, et, al. Therapeutic targets in idiopathic pulmonary fibrosis. Respir Med. 2017 Oct;131:49-57.
CAS Number: 1403859-14-2
Molecular Weight: 321.42
Compound Purity: 99.75
Research Area: Inflammation/Immunology
Solubility: DMSO : 125 mg/mL (ultrasonic)
Target: JNK